PhaseII trial of neoadjuvant chemotherapy with TS-1, Oxaliplatin and Bevacizumab for resectable liver metastases from colorectal cancer - N-SOG 05

agoya Surgical Oncology Group0 个研究点目标入组 60 人开始时间: 2010年12月13日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Active double cancer 2) Active infection 3) Fever of >= 38 degrees Celsius 4) Pregnant or nursing females. Males who are planning partners' pregnancy. 5)Severe mental disorder 6)Systemic administration of corticosteroids 7)Serious complications 8)Abnormal in electrocardiogram within 28 days before chemotherapy or clinically significant heart disease 9)Neuropathy 10)Uncontrolled diarrhea 11)Massive pleural or abdominal effusion 12)Brain metastases 13)History of thromboembolism, cerebral infarction, pulmonary infraction or interstitial pneumonia 14)Surgery within 28 days before chemotherapy 15)History of hypersensitivity for Oxaliplatin 16)History of hypersensitivity for TS-1 17)History of hypersensitivity for Bevacizumab 18)Under treatment with fluoropyrimidine except TS-1 19)Under treatment with flucytosine 20)Pretreatment with TS-1, Oxaliplatin or Bevacizumab 21)High grade stenosis at the primary tumor 22)Massive peritoneum dissemination 23)Bleeding (Congenital hemorrhagic disease) or coagulation disorder 24)Under treatment with anticoagulant 25)History of gastrointestinal perforation within 6 months before registration 26)History of hemoptysis 27)Not suitable for participation with any other reasons

发起方

agoya Surgical Oncology Group